Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 49

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 49
---
 internal application plai . Plai aggregates internal data across all functions and harnesses the power of AI to provide timely insights and personalized “ what if ” development scenarios to support informed decision-making. We also hosted our inaugural global hackathon, enabling over 31,000 Sanofi employees to learn about the AI Agents used in Sanofi operations; • the expansion of our accelerators continued with the launch of two additional accelerators: a digital R&D accelerator, followed by a digital M&S accelerator in 2024; • in Research, we have built multiple AI programs to reduce research times through improved predictive modelling and automated time-sink activities. As a result, AI enables R&D teams to scale and accelerate research processes and improve potential target identification in therapeutic areas like immunology, oncology or neurology by 20 to 30%; • in Manufacturing & Supply, we have developed an in-house AI-enabled yield optimization solution which learns from past and current batch performance in an effort to enable consistently higher yield levels. This optimizes usage of raw materials, supports our environmental efforts and supports improved cost efficiency; and • we have partnered with FormationBio and OpenAI to develop AI-powered software to accelerate drug development, create custom drug development lifecycle solutions and bring new medicines to patients more efficiently: – in 2024 we focused on unifying Sanofi’s approach to data and AI, standardizing our approach to unlock value through shared tools and assets, – Sanofi's internal GenAI tools are maturing rapidly, with Concierge (launched October 2024) and a successful M365 Copilot pilot completed, – over 2,000 new users, across verticals, were trained on GenAI tooling delivered from GenAI Board-approved use cases in 2024, – approximately 7,000 Sanofi employees received training throughout Gen AI courses on SanofiU, our in-house learning platform . 4) Reinvent how we work Transformation and simplification have started, with the aim of increasing empowerment and accountability. To drive implementation of our new culture built on stronger focus, diversity and teamwork, we have streamlined our executive leadership team around 13 members. Three new members were appointed to our Executive Committee in 2024: Brian Foard as Head of the Specialty Care Global Business Unit (succeeding Bill Sibold); François Roger as Chief Financial Officer (succeeding Jean-Baptiste de Chatillon); and Audrey Duval as Global Head of Corporate Affairs. The complete Sanofi Executive Committee now includes the four managers who head up our Global